Company news
Nuvectis Pharma, Inc. news in 2025
Nuvectis Pharma, Inc.'s news releases, calls and decks from 2025, newest first.
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
December 17, 2025
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
November 25, 2025
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 4, 2025
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 4, 2025
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 27, 2025
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2025
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
September 25, 2025
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
August 11, 2025
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
August 5, 2025
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
July 31, 2025
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
July 8, 2025
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2025
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
May 6, 2025
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
April 29, 2025
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
March 26, 2025
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
March 14, 2025
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
March 4, 2025
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
February 25, 2025
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
February 6, 2025
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
February 4, 2025
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
February 3, 2025